# Three in four orthopedic surgeons had payments refused by health plans

In orthopedics, refused claims have become routine: a third of the specialists who take health-plan patients had bills turned down more than ten times in a year. As a result, 88.5% are dissatisfied with what plans pay for surgery, more than the 78.4% who complain about SUS, the public system.

- Section: Business
- Published: November 17, 2026
- Address: https://ceoone.com.br/en/article/three-in-four-orthopedic-surgeons-had-payments-refused-by-health-plans
- Em português: https://ceoone.com.br/artigo/tres-em-cada-quatro-ortopedistas-tiveram-pagamento-negado-por-planos-de-saude.md

![A wall display of hip prostheses in different models, metal stems and polished balls lit against a dark background](https://pub-b80e49b2737940b3ab5d3f20d0578192.r2.dev/artigos/tres-em-cada-quatro-ortopedistas-tiveram-pagamento-negado-por-planos-de-saude-foto.webp)

Photo: FE2656BA/Wikimedia Commons (CC BY-SA 4.0)

## Key points

- Three in four orthopedic surgeons who take health-plan patients (75.2%) had payments refused in the past year, and 32.4% more than ten times.
- As a result, 88.5% disapprove of what plans pay for surgery, more than the 78.4% who complain about SUS; FenaSaúde says refusals fight waste and fraud.
- From February 2027, health plans must cover the NGS genetic test and tepotinib for advanced lung cancer.

The surgeon operates, the patient goes home and, months later, the insurer announces it will not pay part of the bill. In orthopedics, that scene is no longer the exception. Three in four orthopedic surgeons who see health-plan patients (75.2%) had payments refused by the plans in the past year, and almost a third (32.4%) went through it more than ten times.

The figures come from the national survey of 1,326 orthopedic and trauma surgeons in the Medical Demography in Brazil 2027 study, by the University of São Paulo Medical School with the Brazilian Medical Association, the Ministry of Health and the Pan American Health Organization, supported by the Brazilian Society of Orthopedics and Traumatology (Sbot). Interviews took place between October 2025 and July 2026, with a margin of error of 2.2 percentage points.

## Health plans bother them more than SUS

Private health plans are central to the specialty: 91.3% of those surveyed see or operate on plan patients. And that is precisely where dissatisfaction with pay is highest. Among those who operate, 88.5% disapprove of what plans pay for surgery, against 78.4% who complain about SUS fees. Only 3.7% of those operating in private hospitals are satisfied with what they receive.

"We have always criticized health plans in general. But when you drill down into one specialty, the private-sector data are very bad," says Mário Scheffer, professor of preventive medicine at USP and coordinator of the study.

![Chart: how often orthopedic surgeons had payments refused in the past year, what the refusals caused and how many are dissatisfied with surgical fees from health plans (88.5%) and SUS (78.4%)](https://pub-b80e49b2737940b3ab5d3f20d0578192.r2.dev/artigos/tres-em-cada-quatro-ortopedistas-tiveram-pagamento-negado-por-planos-de-saude-grafico-en.webp)

The numbers from the survey of 1,326 orthopedic surgeons. Chart: CEO ONE, with data from Medical Demography in Brazil 2027 (FMUSP, AMB, Ministry of Health and PAHO)

## What a refused claim is

In Brazil, a "glosa" is the total or partial refusal to pay for a consultation, test or surgery already performed. Under the rules of the National Supplementary Health Agency (ANS), it is only allowed when the insurer finds a discrepancy between the bill and the contract, the agency's rules or the patient's health condition. The report says, however, that many doctors describe arbitrary decisions by insurers.

Of the orthopedic surgeons who take plan patients, only 20% had no refusal at all in the past year. Another 19.7% had two to five, 20.6% more than five and 32.4% more than ten.

The most cited consequence was significant financial loss, reported by 622 doctors, 46.9% of those surveyed. Administrative rework (29%), late payment (27.6%) and having to appeal or justify the bill (25.2%) also appear.

## Between the insurer's logic and the service provided

Orthopedic surgeon Fernando Baldy, former president of Sbot and full professor at Unifesp, says the society keeps a professional defense committee devoted to the issue, which meets with insurers. He says he understands the companies' logic. "No insurer likes to work with unpredictability. Every time things go a little off the curve, it refuses the claim. Rationally, we understand. But the colleague provided the service."

For Baldy, the figures show that Sbot's work with the plans is not yet enough. "It is a path still to be travelled."

In a statement, the National Federation of Supplementary Health (FenaSaúde) says refusals are "not an instrument of financial retention" but a technical measure to protect members against waste and fraud. In orthopedics, according to the federation, the main reasons are inconsistencies in requests for orthoses, prostheses and special materials (OPME), charges without proof of use or prior authorization, coding errors and missing clinical documentation.

The federation says technical audits cover only 5% of requests and that, under ANS rules, the insurer must justify each refused item with specific codes, which allows the doctor to contest it and reverse the charge.

## Surgeries that don't happen

The same survey shows that 74.8% of orthopedic surgeons who operate had at least one surgery cancelled in six months. The patient's condition leads the reasons (84.1%), followed by lack of prosthesis or material (39.6%), lack of an operating room or ICU bed (28.7%) and refusal by the plan (25.2%). On this point, the survey does not separate the public and private networks.

## Lung cancer: genetic test and drug added to coverage

On the same day the survey came out, health plans got a new obligation. On Monday (16), the ANS published in the Official Gazette the rule requiring insurers to cover the next-generation sequencing (NGS) panel for patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The measure takes effect on February 1, 2027.

The test identifies genetic alterations in the tumor and helps choose the most suitable treatment. The resolution also extends coverage of tepotinib hydrochloride, an oral drug for the first-line treatment of adults with advanced NSCLC carrying an alteration in the MET gene known as METex14.

According to geneticist Cristovam Scapulatempo, medical director of Pathology and Genomics at Dasa Genômica, next-generation sequencing analyzes several tumor mutations at once, making diagnosis faster and more precise. In lung cancer, the analysis is done on a sample of tumor tissue or, when there is not enough material, on blood plasma, in what is called a liquid biopsy.

## Sources and editorial notes

- Based on reporting by Cláudia Collucci and Laiz Menezes published in Folha de S.Paulo (Health section) on November 17, 2026, with data from the Medical Demography in Brazil 2027 study (FMUSP, AMB, Ministry of Health and PAHO).

CEO ONE · https://ceoone.com.br

